CD14 and neoplasm: In the tumor ROI, we focused on stromal and epithelial tumor compartments and assessed their infiltration by monocytic CD11b+CD14+, granulocytic CD11b+CD15+, and immunosuppressive ARG1+ myeloid cells and also CD8+Ki67+/– cytotoxic and FOXP3+ regulatory T cells.